Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,979 | -2,711 | -2,189 | -3,656 | -9,589 |
| Depreciation Amortization | 3,441 | 3,897 | 4,925 | 5,008 | 6,296 |
| Accounts receivable | -662 | -536 | -1,010 | -454 | 375 |
| Other Working Capital | -1,852 | -546 | -2,165 | -1,185 | 239 |
| Other Operating Activity | 2,945 | 994 | 1,570 | 1,769 | 3,083 |
| Operating Cash Flow | $-1,107 | $1,098 | $1,131 | $1,482 | $404 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | N/A | 538 |
| PPE Investments | -3,685 | -2,069 | -1,449 | -1,228 | -8,246 |
| Net Acquisitions | N/A | -892 | -102 | N/A | N/A |
| Other Investing Activity | -1,823 | 0 | 0 | 0 | 138 |
| Investing Cash Flow | $-5,508 | $-2,961 | $-1,551 | $-1,228 | $-7,570 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 16,631 | 24,614 | 20,694 | 26,624 |
| Debt Repayment | -2,729 | -18,397 | -25,048 | -22,735 | -26,232 |
| Common Stock Issued | 13,498 | 5,555 | 135 | 895 | 7,918 |
| Financing Cash Flow | $10,769 | $3,789 | $-299 | $-1,146 | $8,310 |
| Exchange Rate Effect | 53 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 2,503 | 577 | 1,296 | 2,188 | 1,044 |
| End Cash Position | 6,710 | 2,503 | 577 | 1,296 | 2,188 |
| Net Cash Flow | $4,207 | $1,926 | $-719 | $-892 | $1,144 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,107 | 1,098 | 1,131 | 1,482 | 404 |
| Capital Expenditure | -3,685 | -2,069 | -1,449 | -1,228 | -8,246 |
| Free Cash Flow | -4,792 | -971 | -318 | 254 | -7,842 |